Addition of Lactobacillus to Metronidazole in Treatment of CDAD

• Status: Withdrawn
• Trial end date: 2010-07-31
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to determine whether dietary supplementation with Lactobacillus GG will reduce the rate of failure or relapse following treatment of CDAD with metronidazole.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Michael E. DeBakey VA Medical Center; VA Medical Center, Houston
• Collaborator: Baylor College of Medicine
• Treatments: Metronidazole

Criteria

Inclusion Criteria:

• Subjects will be identified based on the diagnosis of CDAD. This diagnosis is made bases on the presence of diarrhea, fever, abdominal pain and/or leukocytosis together with a positive fecal assay for Clostridium difficile toxin

Exclusion Criteria:

• Patients who are unable to take oral medications and those with underlying gastrointestinal disease or colonostomy will be excluded.

• Patients currently taking penicillins, cephalosporins, quinolones or tetracyclines will be excluded because these drugs are active against Lactobacillus.